Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...